Literature DB >> 16648101

Recommendations for treatment with IMRT for prostate and head-neck cancer. Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia.

M del Carmen Maceira Rozas1, Teresa Rey Liste, Angela L García Caeiro, Julio García Comesaña.   

Abstract

Intensity-modulated radiation therapy (IMRT) is an advanced form of radiotherapy for the treatment of cancer that allows, on one hand, to administer a more homogeneous dose to the patients on the volume to irradiate (which would increase the local control of the disease), and on the other hand, to diminish the toxicity in the organs at risk. This type of treatment is based on imaging techniques, on computer dosimetry programs, and on more precise immobilization accessories. Before delivering IMRT it is necessary to establish a protocol that includes the different phases of the treatment process, that is, the obtaining of anatomical data, beam definition, calculation, dose distribution, and treatment performance and control. In this article we present the basic standards for the IMRT treatment for prostate and head-neck cancer agreed upon a consensus meeting. The follow-up of the recommendations settled down in this document will help in the establishment of a standardized clinical practice -assuring the quality- and a better evaluation of the results of the clinical intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16648101     DOI: 10.1007/BF02664936

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  9 in total

Review 1.  Intensity modulated radiation therapy: a clinical review.

Authors:  C Nutting; D P Dearnaley; S Webb
Journal:  Br J Radiol       Date:  2000-05       Impact factor: 3.039

Review 2.  Intensity-modulated radiotherapy: current status and issues of interest.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-15       Impact factor: 7.038

3.  Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.

Authors:  Patrick A Kupelian; Chandana A Reddy; Thomas P Carlson; Kimberley A Altsman; Twyla R Willoughby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

4.  A survey of intensity-modulated radiation therapy use in the United States.

Authors:  Loren K Mell; John C Roeske; Arno J Mundt
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

5.  Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques.

Authors:  K S Chao; N Majhail; C J Huang; J R Simpson; C A Perez; B Haughey; G Spector
Journal:  Radiother Oncol       Date:  2001-12       Impact factor: 6.280

6.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

7.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.

Authors:  Michael J Zelefsky; Zvi Fuks; Margie Hunt; Yoshiya Yamada; Christine Marion; C Clifton Ling; Howard Amols; E S Venkatraman; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.

Authors:  H K Shu; T T Lee; E Vigneauly; P Xia; B Pickett; T L Phillips; M Roach
Journal:  Urology       Date:  2001-01       Impact factor: 2.649

9.  Norwegian oncologists' expectations of intensity-modulated radiotherapy.

Authors:  Ludvig P Muren; Olav Mella; Rune Hafslund; Olav Dahl
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.